Pfizer On Obamacare Rewind: No Short-Term Impact On Industry
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
You may also be interested in...
The failure of the GOP effort to repeal the Affordable Care Act came after a lot of health care stakeholders warned that proposals in the Senate would lead to a disaster. The pharmaceutical industry maintained its silence on the bill – and probably ends up as one of the winners as the dust settles.
Brand name industry’s image campaign promises to 'Go Boldly' – but there has been nothing bold about its public response to the Trump Administration’s efforts to repeal the Affordable Care Act, the President’s strong words on drug pricing, or even proposed cuts to NIH funding and FDA. Treading carefully makes a lot of sense – but is there a line that PhRMA won’t let the Administration cross?
Medicaid block grant funding mechanism, which could allow states to bypass coverage requirements in the Medicaid drug rebate program, surfaces in House American Health Care Act.